```
=> file medline hcaplus biosis biotechds embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 13:21:42 ON 04 FEB 2005

FILE 'HCAPLUS' ENTERED AT 13:21:42 ON 04 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:21:42 ON 04 FEB 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 13:21:42 ON 04 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 13:21:42 ON 04 FEB 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

=> s AP-dextran conjugate
L1            1 AP-DEXTRAN CONJUGATE

=> d l1

L1   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:133978  HCAPLUS
DN   140:177309
TI   Tissue non-specific alkaline phosphatase conjugate with dextran and its
     use as standard for quantitative AP assay
IN   Schneidinger, Bernd; Meier, Thomas; Schmuck, Rainer; Xiao, Ji-Xing
PA   F. Hoffmann-La Roche Aktiengesellschaft, Switz.
SO   Jpn. Kokai Tokkyo Koho, 14 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   JP 2004049240         A2    20040219    JP 2003-276312          20030717
     CA 2433479            AA    20040122    CA 2003-2433479         20030716
     EP 1405907            A2    20040407    EP 2003-16363           20030719
     EP 1405907            A3    20041013
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2004082027         A1    20040429    US 2003-624154          20030721
PRAI EP 2002-16244         A     20020722


=> s alkaline phosphatase and dextran
L2          469 ALKALINE PHOSPHATASE AND DEXTRAN

=> s alkaline phosphatase and dextran conjugate?
L3            9 ALKALINE PHOSPHATASE AND DEXTRAN CONJUGATE?

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4             6 DUP REM L3 (3 DUPLICATES REMOVED)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L5           280 DUP REM L2 (189 DUPLICATES REMOVED)

=> d l4 1-6 ibib ab
```

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:902115 HCAPLUS
DOCUMENT NUMBER: 141:384388
TITLE: Morpholino imaging and therapy via amplification targeting
INVENTOR(S): Hnatowich, Donald J.; He, Jiang; Liu, Guozheng; Gupta, Suresh; Zhang, Yumin; Rusckowski, Mary
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091525	A2	20041028	WO 2004-US11517	20040415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-462692P P 20030415

AB The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathol. condition. The kit comprises, in sep. containers, (A) a first conjugate comprising a targeting moiety and a morpholino oligomer (MORF), wherein said targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or assocd. with the target site; (B) optionally, a clearing agent; (C) a second conjugate comprising multiple copies of complementary morpholino oligomer (cMORF) and a diagnostic agent or therapeutic agent; wherein the CMORF is bound to a polymer; and (D) a third conjugate comprising a MORF and a radiolabel. The method for targeting of a diagnostic or therapeutic agent comprises administering (A), optionally (B), (C) and (D) to a mammal. For example, whole body images obtained simultaneously of three nude mice each bearing LS174T tumors were presented. The first animal received MORF-99mTc (3 h before imaging), the second one received MORF-99mTc and the cMORF-polymer (21 h before imaging), while the study animal (amplification) received the MORF-99mTc, cMORF-polymer, and the anti-CEA antibody (MN14)-MORF (51 h before imaging). The images show tumor only in the study animals receiving both the antibody and the polymer, providing evidence that in vivo amplification targeting is feasible and has been achieved.

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:133978 HCAPLUS
DOCUMENT NUMBER: 140:177309
TITLE: Tissue non-specific **alkaline phosphatase** conjugate with dextran and its use as standard for quantitative AP assay
INVENTOR(S): Schneidinger, Bernd; Meier, Thomas; Schmuck, Rainer; Xiao, Ji-Xing
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Aktiengesellschaft, Switz.
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004049240	A2	20040219	JP 2003-276312	20030717
CA 2433479	AA	20040122	CA 2003-2433479	20030716
EP 1405907	A2	20040407	EP 2003-16363	20030719
EP 1405907	A3	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004082027	A1	20040429	US 2003-624154	20030721
PRIORITY APPLN. INFO.:			EP 2002-16244 A	20020722

AB **Dextran conjugate** of tissue non-specific alk. phosphatase (tns-AP) obtained by reacting nonglycosylated tns-AP and activated dextran in aq. soln., and use of the AP-**dextran conjugate** as std. for quant. AP assay, are disclosed. Nonglycosylated tns-AP can be obtained by expressing tns-AP in prokaryotes. Expression of human tns-AP in E. coli, and conjugation with dextran T-40 (av. mol. wt. 40 kDa) are described. After dextran conjugation, the activity of tns-AP was 70 ~ 90% of the non-conjugated tns-AP.

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:777993 HCAPLUS
DOCUMENT NUMBER: 139:287262
TITLE: PNA probes derived from ribosomal DNA for the diagnostic detection of Bacillus anthracis
INVENTOR(S): Stender, Henrik; Hyldig-Nielsen, Jens J.
PATENT ASSIGNEE(S): Boston Probes, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080857	A2	20031002	WO 2003-US8890	20030321
WO 2003080857	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232402	A1	20031218	US 2003-393855	20030321
EP 1487858	A2	20041222	EP 2003-723808	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-366424P P	20020321
			WO 2003-US8890 W	20030321

AB Peptide nucleic acid probes derived from ribosomal DNA are described for the detn. of Bacillus anthracis. Specificity of the probes for B. anthracis in fluorescent in situ hybridization is demonstrated.

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:784342 HCAPLUS
DOCUMENT NUMBER: 132:10507

TITLE: Modified DELISA immunoassay for the detection of autoantibodies and other analytes
INVENTOR(S): Mehta, Harshvardhan B.; Kurn, Nurith
PATENT ASSIGNEE(S): Dade Behring Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963345 A1		19991209	WO 1999-US11446	19990524
W: JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1998-87839 19980529

AB The invention relates to methods of detg. the presence or amt. of an analyte in a sample suspected of contg. the analyte, said method comprising the steps of: (a) bringing together in an aq. medium to form a mixt.: (i) the sample; (ii) at least one specific binder for the analyte; (iii) a first binding agent coupled to either (1) exogenous analyte or (2) the specific binder for the analyte; (iv) a support comprising a second binding agent; (b) adding an activator to the mixt., wherein the activator binds the first binding agent and the second binding agent of the support to immobilize the first binding agent; (c) detg. the amt. of the analyte in the sample by detecting the immobilized first binding agent, the presence or amt. thereof being related to the presence or amt. of the analyte in the sample. The invention also relates to a modified DELISA assay in which the analyte is an antibody/autoantibody; the binding mol. is an antigen to the antibody, the first binding agent is coupled to exogenous antigen. Thsu anti GAD (glutamic acid decarboxylase) autoantibody was detd. in the sera of IDDM (insulin dependent diabetes mellitus) patients using a one plate assay. Biotinylated BSA was immobilized to Nunc U8 maxisorp microtiterplate; biotinylated GAD soln. was incubated with the sample on the plate; thereafter protein A reagent was added, followed by incubation and the addn. of a streptavidin reagent. Finally the plate was rinsed; monoclonal antibody-HRP conjugate was added; after incubation, tetra-Me benzidine and hydrogen peroxidase were added; the intensity was measured at 630 nm in a plate reader.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:120484 HCAPLUS
DOCUMENT NUMBER: 118:120484
TITLE: Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
INVENTOR(S): Lihme, Allan Otto Fog; Boenisch, Thomas
PATENT ASSIGNEE(S): Immunodex K/S, Den.
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301498	A1	19930121	WO 1992-DK206	19920629
W: AU, CA, CS, FI, HU, JP, KP, KR, NO, PL, RO, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5543332	A	19960806	US 1991-789757	19911108
CA 2112992	AA	19930121	CA 1992-2112992	19920629
CA 2112992	C	20020611		
AU 9223489	A1	19930211	AU 1992-23489	19920629

AU 667051	B2	19960307			
EP 594772	A1	19940504	EP 1992-916161		19920629
EP 594772	B1	19960828			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE					
AT 142021	E	19960915	AT 1992-916161		19920629
ES 2094920	T3	19970201	ES 1992-916161		19920629
JP 3340434	B2	20021105	JP 1993-501899		19920629
NO 9400030	A	19940303	NO 1994-30		19940104
PRIORITY APPLN. INFO.:			DK 1991-1309	A	19910704
			US 1991-789757	A	19911108
			WO 1992-DK206	A	19920629

AB Water-sol. reagents and conjugates which are particularly well suited for use, for example, in biol. relevant detection, quantification, and targetting procedures, e.g. in immunohistochem., antibody immobilization, sepn., or purifn., DNA hybridization tests, and flow cytometry, are based on a polymeric carrier to which are covalently attached .gtoreq.1 moieties derived from divinyl sulfone, each of which moieties is attached to the carrier via a covalent linkage formed between one of the 2 vinyl groups of a divinyl sulfone and a reactive functionality on the polymeric carrier. The mol. species, of which .gtoreq.1 may be attached to a carrier mol., is an antigen, antibody, hapten, gene probe, hormone, enzyme, drug, dye, fluorophore, etc. Methods are provided for the prepn. of the reagents and conjugates. High-mol.-wt. dextran was activated by reaction with divinyl sulfone and then coupled with horseradish peroxidase and with straptavidin. The conjugate was complexed with biotinylated rabbit anti-human .kappa. light chain. The complex was tested in an ELISA and in an immunohistochem. procedure.

L4 ANSWER 6 OF 6 MEDLINE on STN DUPLICATE 2

ACCESSION NUMBER:	94086252 MEDLINE
DOCUMENT NUMBER:	PubMed ID: 7505268
TITLE:	Phase I clinical and pharmacokinetic trial of **dextran conjugated** doxorubicin (AD-70, DOX-OXD).
AUTHOR:	Danhauser-Riedl S; Hausmann E; Schick H D; Bender R; Dietzfelbinger H; Rastetter J; Hanauske A R
CORPORATE SOURCE:	Department of Medicine I, Technische Universitat Munchen, Germany.
SOURCE:	Investigational new drugs, (1993 May-Aug) 11 (2-3) 187-95. Journal code: 8309330. ISSN: 0167-6997.
PUB. COUNTRY:	United States
DOCUMENT TYPE:	(CLINICAL TRIAL) (CLINICAL TRIAL, PHASE I) Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:	English
FILE SEGMENT:	Priority Journals
ENTRY MONTH:	199401
ENTRY DATE:	Entered STN: 19940209 Last Updated on STN: 19960129 Entered Medline: 19940124

AB Coupling of anthracyclines to high-molecular-weight carriers may alter drug disposition and improve antitumor effects. We have performed a clinical phase I trial of doxorubicin coupled to dextran (70000 m.w.). The drug was administered as single dose i.v. every 21-28 days. Thirteen patients have received a total of 24 courses (median 2; range 1-3). At the starting dose of 40 mg/m2 doxorubicin equivalent (DOXeq), WHO grade IV thrombocytopenia was noted in 2/2 patients. WHO grade IV hepatotoxicity and WHO grade III cardiotoxicity were noted in a patient with preexisting heart disease. Five patients were treated with 12.5 mg/m2 DOXeq. Maximal toxicity at this dose level was WHO grade III thrombocytopenia and local phlebitis (WHO grade II) in 1/5 patients, elevation of **alkaline phosphatase** (WHO grade III) and WHO grade III vomiting in another patient. Subsequently, five patients received 20 mg/m2 DOXeq. Hepatotoxicity was noted in 5/5 patients (1 x WHO grade IV, 1 x WHO grade III). Thrombocytopenia was noted in 3/5 patients (1 x WHO grade IV, 2 x

WHO grade III). At 12.5 mg/m2 DOXeq, a patient diagnosed with a malignant fibrous histiocytoma had stable disease for 4 months. Pharmacokinetic analyses of total and free doxorubicin were performed in plasma and urine. The maximum peak plasma concentration (ppc) for total DOX was 12.3 micrograms/ml at 40 mg/m2 DOXeq. The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t1/2 alpha: 0.02-0.87 h; t1/2 beta: 2.69-11.58 h; t1/2 gamma: 41.44-136.58 h).(ABSTRACT TRUNCATED AT 250 WORDS)

=> d his

(FILE 'HOME' ENTERED AT 13:21:11 ON 04 FEB 2005)

FILE 'MEDLINE, HCAPLUS, BIOSIS, BIOTECHDS, EMBASE' ENTERED AT 13:21:42 ON 04 FEB 2005

```
L1             1 S AP-DEXTRAN CONJUGATE
L2           469 S ALKALINE PHOSPHATASE AND DEXTRAN
L3             9 S ALKALINE PHOSPHATASE AND DEXTRAN CONJUGATE?
L4             6 DUP REM L3 (3 DUPLICATES REMOVED)
L5           280 DUP REM L2 (189 DUPLICATES REMOVED)
```

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.54	23.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

STN INTERNATIONAL LOGOFF AT 13:25:42 ON 04 FEB 2005